5-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Reminds Investors with Losses to Contact the Firm

Wednesday, April 5, 2017 5:16 PM UTC

IRVINE, Calif., April 05, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Kitov Pharmaceuticals Holdings Ltd (“Kitov” or the “Company”) (Nasdaq:KTOV). Investors who purchased Kitov American Depositary Receipts (“ADRs”) pursuant to the Company’s initial public offering on or about November 20, 2015 (the “IPO”) and/or between November 20, 2015 and February 3, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm before the April 10, 2017 lead plaintiff motion deadline.

If you purchased Kitov shares during the IPO or Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, Kitov made false and/or misleading statements and/or failed to disclose that the Company and its CEO Isaac Israel, published misleading information concerning the conduct of the Company’s clinical trials for its lead drug candidate, KIT-302, and consequently, Kitov’s public statements were materially false and misleading at all relevant times. On February 6, 2017, Calcalist, an Israeli publication, reported that Isaac Israel was detained and questioned by the Israeli Securities Authority for allegedly publishing misleading information about the Company’s recent clinical trial.

If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

5-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Reminds Investors with Losses to Contact the Firm

Editor's Picks

Welcome to EconoTimes